logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

The new European harmonization of clinical trials, an opportunity to attract more investment to Spain

Since yesterday, the new Clinical Trials Information System (CTIS) has been operational, which centralizes processes with the aim of speeding up these studies

Our country starts with an advantage, because it was the first to adopt European regulations and because of the coordinated work carried out by public and private agents, which has positioned us as an international reference

This excellence in clinical trials can be the basis for creating a solid biomedical research ecosystem, which also promotes basic and preclinical research and makes Spain one of the leading countries in drug research

Source: www.farmaindustria.es

The way in which clinical trials are carried out in the European Union (EU) is going to undergo important changes for the benefit of patients. Since yesterday, January 31, the Clinical Trials Information System (CTIS) has become operational, which harmonizes the processes of presentation, evaluation and supervision of clinical trials in the region, with the aim to speed up these studies and, consequently, that new effective and safe medicines reach the people who need them sooner.

With the CTIS, clinical trial sponsors can request authorization for a clinical trial, simultaneously, in all EU countries with a single application that covers submissions to competent national authorities, ethics committees and public registration of the clinical trial .

The European Medicines Agency (EMA) has stipulated that Member States work on the CTIS from its launch, as soon as clinical trial applications are submitted to them through the new system. The promoters will be able to use the new system or the previous one for a year, but from January 31, 2023 they will have to use the centralized platform for the new trials they want to launch. Finally, the EMA has set a transitional period of three years, and all the information on these studies must be fully transferred by 2025.

Spain starts out in an advantageous position in this area, since it was the first country in the EU to adopt the European Regulation on Clinical Trials -in which the CTIS is framed-. It did so with Royal Decree 1090/2015 and this has led to the simplification and harmonization of procedures at the national level before any other Member State; the reduction of times in the start-up of the studies; an increase in trials in early phases, which are those that require a higher level of complexity, and a greater commitment to research in rare diseases and in the pediatric population.

Our country has also been one of the first to carry out the necessary training for the use of this new platform. Coordinated by the Spanish Agency for Medicines and Health Products (Aemps), and in collaboration with Farmaindustria, preparation meetings have been held since the end of last year with technicians from the agency for pharmaceutical companies and members of the ethics committees in the investigation of medicines (CEIm). “In fact, many of those responsible for the new process to develop clinical trials in our laboratories in Europe are Spanish because they already have experience in simplifying processes and coordinating between agents,” says Amelia Martín Uranga, associate director of Clinical Research and Translational of Farmaindustria.

Competitive advantage for Spain

Accustomed to this coordinated and collaborative way of working, Spain has become an international reference in clinical trials – the cornerstone of the development of new medicines -, which constitutes a very good competitive advantage for our country to continue growing and attract even more investment .

And it is that the trials not only offer new hope for patients, but also have very positive economic consequences for the health system. They attract financing from the promoting pharmaceutical companies to the participating hospitals, both public and private, and represent the first source of private income for the centers. In addition, they add reputation, experience and knowledge to the health professionals who perform them, placing them at the scientific forefront, which they can apply in their care work.

“The joint work between all the actors, public and private, has made it possible to update and optimize the management of clinical trials, and this collaboration has had its reflection during the pandemic, since we have become the first country in Europe and the fourth in the world. world by number of clinical trials for Covid-19”, recalls Martín Uranga. “Today there are some 3,500 drug clinical trials underway in Spain, in which more than 130,000 patients participate,” she adds.

Another proof of Spain’s capacity in clinical research is that, in some of the international trials with Spanish participation, according to data from the companies themselves, our country has been the first to launch the research project, in record time, and even in some cases the first patient to enter the clinical trial was Spanish.

Currently, researchers and health centers in Spain already participate in one out of every three clinical trials carried out in Europe, and for some of these companies, Spain is already the preferred destination for their investments in clinical research after the United States. Another fact: in 2020, 1,027 authorized clinical trials were reached in Spain, a historical record, according to the data

Related entries

2 October, 2023

Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research


Leer más
26 September, 2023

More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society


Leer más
19 September, 2023

The pharmaceutical industry’s plan to expand clinical trials in primary care


Leer más

Recent Posts

  • Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research
  • More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society
  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros
  • Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.